MedCheck: FDA Approves Caplyta as Depression Adjunct, Chooses Cytisinicline for ‘Priority Voucher’ Program, and More | Psychiatric News
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has approved Caplyta as an adjunct treatment for depression. Additionally, the FDA has chosen Cytisinicline for its 'Priority Voucher' program. These developments are among several recent updates reported by MedCheck.